---
title: "DAP C - Tier II Community Urology and Gynaecology services - 27-28"
ocid: "ocds-h6vhtk-07b310"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-07b310"
markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-07b310.md"
json_url: "https://d3tenders.com/contract/ocds-h6vhtk-07b310.json"
source: "Find A Tender Service"
current_stage: "Award"
buyer: "NHS Essex Integrated Care Board"
published: "2026-11-12"
---

# DAP C - Tier II Community Urology and Gynaecology services - 27-28

Buyer: NHS Essex Integrated Care Board  
Current stage: Award  
OCID: ocds-h6vhtk-07b310

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-07b310)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-07b310.json)

## Summary

NHS Essex Integrated Care Board commissioned community-based Tier II dermatology services for people in south west Essex. The service is intended to provide specialist assessment and treatment closer to home, support management of long-term skin conditions and help reduce pressure on hospital services where clinically appropriate. It forms part of the wider dermatology pathway, with patients needing specialist or hospital intervention referred to acute providers. The work includes triage and management of referrals, diagnosis and treatment, and collaboration with primary and secondary care. The provider is expected to deliver safe, evidence-based care and timely access to dermatology expertise. The service was previously managed by Mayflower Healthcare Alliance, and commissioning responsibility transferred to the Essex ICB during an ICB reorganisation.

The contract has been awarded to the existing provider, Mayflower Healthcare Alliance, through Direct Award Process C under the Health Care Services (Provider Selection Regime) Regulations 2023, without a prior competition. The contract is active and was signed on 26 October 2026. Its stated value is £819,043. The procurement describes the service as an indicative block contract based on 2026/27 activity, with the value subject to national inflator or deflator calculations. The proposed arrangement continues the existing service without considerable changes. Evaluation weighted quality and innovation at 40%, value at 30%, integration, collaboration and sustainability at 15%, access, health inequalities and choice at 10%, and social value at 5%. The provider was assessed against these criteria and judged to meet the requirements.

This award shows demand for specialist community dermatology that can deliver assessment, diagnosis, treatment and referral through an established clinical pathway, while managing suitable care outside acute settings. A credible future competitor would need to demonstrate safe, evidence-based clinical practice, dependable triage and referral management, timely access to specialist expertise, and the ability to support patients with long-term skin conditions. Strong working relationships with primary and secondary care would be important, alongside a sustainable service model that maintains agreed quality and performance standards. The assessment also shows that the buyer considers value for public money, equitable access and patient choice, and social value, in addition to clinical quality. Suppliers should be able to evidence effective coordination with acute providers and delivery that helps reserve hospital services for patients with more complex needs.

## Notice

The community dermatology service is currently delivered by Mayflower Healthcare Alliance (MHA). This contract was passed to Essex ICB from NHS Hertfordshire and West Essex ICB as part of the ICB reorganisations in April 2026. It provides community-based dermatology services for the local population. Mayflower Healthcare Alliance has an established role in delivering dermatology care, supporting timely access to specialist assessment and treatment outside of the acute setting. This contract focuses on the delivery of community dermatology services, helping to manage patient demand closer to home and reducing pressures on secondary care providers where clinically appropriate. The service forms part of the wider dermatology pathway and works collaboratively with acute providers to ensure patients requiring specialist or hospital-based interventions are referred appropriately. The commissioning responsibility for this contract transferred to Essex ICB as part of the ICB reorganisation in April 2026. The contract is indicative and based on the 26/27 activity and for the purposes of clarity the value will be subject to the national inflator/deflator calculations. The relevant authority determined that Direct Award Process C applies because Mayflower Healthcare Alliance is the existing provider, the existing contract is due to end, the proposed contracting arrangements are not changing considerably, and the provider is satisfying the existing contract and is likely to satisfy the proposed contract to a sufficient standard.

### Lot Information

Lot 1

The community dermatology service is currently delivered by Mayflower Healthcare Alliance (MHA). This contract was passed to Essex ICB from NHS Hertfordshire and West Essex ICB as part of the ICB reorganisations in April 2026. It provides community-based dermatology services for the local population. Mayflower Healthcare Alliance has an established role in delivering dermatology care, supporting timely access to specialist assessment and treatment outside of the acute setting. This contract focuses on the delivery of community dermatology services, helping to manage patient demand closer to home and reducing pressures on secondary care providers where clinically appropriate. The service forms part of the wider dermatology pathway and works collaboratively with acute providers to ensure patients requiring specialist or hospital-based interventions are referred appropriately. The commissioning responsibility for this contract transferred to Essex ICB as part of the ICB reorganisation in April 2026. The contract is indicative and based on the 26/27 activity and for the purposes of clarity the value will be subject to the national inflator/deflator calculations. The relevant authority determined that Direct Award Process C applies because Mayflower Healthcare Alliance is the existing provider, the existing contract is due to end, the proposed contracting arrangements are not changing considerably, and the provider is satisfying the existing contract and is likely to satisfy the proposed contract to a sufficient standard. The providers have been assessed against the criteria specified for this DAP C process: Quality & Innovation 40%. Quality should be the primary consideration because community dermatology is a specialist clinical service that requires accurate assessment, diagnosis, treatment and referral within an agreed clinical pathway. The service must consistently deliver safe, evidence-based care, provide timely access to specialist dermatology expertise, ensure appropriate triage and management of referrals, and support patients to manage long-term skin conditions closer to home. High-quality delivery is directly linked to improved patient outcomes, reduced waiting times, increased patient satisfaction, and a reduction in unnecessary referrals to secondary care, ensuring specialist acute services are reserved for patients with the most complex needs. Value 30%. It is a statutory duty to ensure the best use of public resources, therefore value has the second highest weighting Integration, Collaboration & Service Sustainability 15%, It is essential for good collaboration between provider, primary and secondary care Access Health Inequalities and Choice 10%; Access to community services are important to ensure not all patients are referred into an acute setting where appropriate Social Value 5%. Although the main focus of the specialist fertility service is to provide healthcare, a weighting of 5% has been allocated to reflect the ICB priority towards the importance of social value Key criteria were specified, and assessment against each criterion was assessed based as above and on the current service delivery model and performance. and the supplier meets all the requirements specified to the satisfaction of the ICB, and it is expected that they will satisfy the requirements of the new contract. NHS Essex Integrated Care Board (the Authority) intends to award a contract for the provision of Tier II Dermatology Services to the existing provider named above following Direct Award Process C under the Health Care Services (Provider Selection Regime) Regulations 2023.

### Procurement Information

This is a Direct Award Process C intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For avoidance of doubt, the provisions of the Public Contract Regulations 2015 and Procurement Act do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to decision makers by midnight Tuesday, 17 November 2026. The contract has not yet formally been awarded, this notice serves as an intention to award under PSR. The Authority has undertaken an appropriate and proportionate review of declarations and is satisfied that effective arrangements are in place to identify and manage any actual, potential, or perceived conflicts of interest. Where relevant, mitigation measures have been applied to ensure that no conflict is capable of conferring any undue advantage or disadvantage. On this basis, the Authority is satisfied that no conflict of interest has adversely affected, or is capable of adversely affecting, the integrity of the procurement. The provider has been assessed against the criteria specified for this DAP C process: Quality & Innovation 40%. Quality should be the primary consideration because community dermatology is a specialist clinical service that requires accurate assessment, diagnosis, treatment and referral within an agreed clinical pathway. The service must consistently deliver safe, evidence-based care, provide timely access to specialist dermatology expertise, ensure appropriate triage and management of referrals, and support patients to manage long-term skin conditions closer to home. High-quality delivery is directly linked to improved patient outcomes, reduced waiting times, increased patient satisfaction, and a reduction in unnecessary referrals to secondary care, ensuring specialist acute services are reserved for patients with the most complex needs. Value 30%. It is a statutory duty to ensure the best use of public resources, therefore value has the second highest weighting Integration, Collaboration & Service Sustainability 15%, It is essential for good collaboration between provider, primary and secondary care Access Health Inequalities and Choice 10%; Access to community services are important to ensure not all patients are referred into an acute setting where appropriate Social Value 5%. Although the main focus of the specialist fertility service is to provide healthcare, a weighting of 5% has been allocated to reflect the ICB priority towards the importance of social value Key criteria were specified, and assessment against each criterion was assessed based as above and on the current service delivery model and performance. and the supplier meets all the requirements specified to the satisfaction of the ICB, and it is expected that they will satisfy the requirements of the new contract. NHS Essex Integrated Care Board (the Authority) intends to award a contract for the provision of Tier II Dermatology Services to the existing provider named above following Direct Award Process C under the Health Care Services (Provider Selection Regime) Regulations 2023.

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Find A Tender Service |
| Latest notice | https://www.find-tender.service.gov.uk/Notice/107694-2026 |
| Notice type | Tender Notice |
| Procurement type | Standard |
| Procurement category | Services |
| Procurement method | Limited |
| Procurement method details | Award procedure without prior publication of a call for competition |
| Tender suitability | Not specified |
| Awardee scale | Large |
| All stages | Tender, Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 12 Nov 2026 |
| Submission deadline | Not specified |
| Future notice date | Not specified |
| Award date | Not specified |
| Contract period | Not specified |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | Not specified |
| Lots value | Not specified |
| Awards value | Not specified |
| Contracts value | £819,043 |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Cancelled |
| Awards status | Active |
| Contracts status | Active |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | NHS Essex Integrated Care Board |
| Locality | CHELMSFORD |
| Postcode area | Chelmsford |
| Postcode | CM1 1QH |
| Country | England |
| ITL 1 | TLH East (England) |
| ITL 2 | TLH3 Essex |
| ITL 3 | TLH36 Heart of Essex |
| Local authority | Chelmsford |
| Electoral ward | Moulsham and Central |
| Westminster constituency | Chelmsford |
| Delivery location | TLH3 Essex |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 1 |
| Supplier names | Mayflower Healthcare Alliance |

## CPV Codes

### Divisions

- 85 - Health and social work services

### Codes

- 85110000 - Hospital and related services

## Release History

- 12 Nov 2026 at 15:52 - TenderUpdate - Tender Notice - https://www.find-tender.service.gov.uk/Notice/107694-2026
- 4 Nov 2026 at 14:51 - Award - Award Notice - https://www.find-tender.service.gov.uk/Notice/104757-2026

## Notice URLs

- https://www.essex.icb.nhs

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-07b310. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-07b310.json.
